ENGAGE run · e72aa5e5ea71

```json [ { "id": 1, "name": "AI Clinical Decision Support, Liability & Care Delivery", "description": "Arguments about AI/ML tools deployed in diagnosis, treatment recommendations, clinical workflow, and care pathways — covering adoption barriers, accuracy versus physician judgment, liability vacuums when AI causes errors, alert fatigue, ambient scribing, and the structural incompat

```json [ { "post_index": 2, "cluster_ids": [20, 24], "claim": "Hotel fraud masquerading as nursing home care extracts hundreds of millions", "argument_type": "personal_anecdote", "stance": "challenges_status_quo", "hyde_excerpt": "Home health and nursing care billing remains structurally vulnerable to fraud because regulatory oversight relies on provider attestation rath

```json [ { "post_index": 36, "matched_article_id": 531, "match_confidence": 87, "match_reason": "The tweet claims AI will displace radiologists most among physician specialties because AI outperforms world-renowned radiologists on CT/MRCP reads; article 531 explicitly analyzes how AI augmentation is raising radiology compensation as a multiplier rather than suppressing it, and m

The cost piece is real, but what I found is that the damage starts way earlier and cheaper. Consumer AI platforms routinely spit out 6-8 supplement recommendations (vitamin D, omega-3s, magnesium, the usual stack) from a routine lab upload, and that's where the escalation of commitment kicks in: monitoring tests, specialist referrals, complementary treatments, all without clinical justification. B

Hinton said the same thing in 2016, and radiology starting offers are now commonly above $600K. The mechanism worth watching is what happens when Aidoc or Viz.ai flags a finding in under 90 seconds and the radiologist uses that to read four times the volume in a shift. That is not replacement. That is a billing multiplier, and the compensation data tracks exactly that way. The gastro's lecture p

That $30k figure is where the conflict of interest actually starts, not ends. An employer carrying that cost per head has a direct financial incentive to know which employees are high-risk claimants before they hire them, and to quietly shed them before they file. That's not paranoia, that's math. What I found when I mapped this out: 78% of self-funded employers already receive employee-specific

The accuracy gap is real. But accuracy is not the same as accountability. When o1-preview misses that 77th case, who gets named in the suit? Not OpenAI. The attending does, under the same reasonable physician standard that existed before any of this was possible. That asymmetry is the actual story here. The Harvard result will accelerate adoption pressure on physicians without changing the contr

The AlphaFold mention is the one worth sitting with longer. Hassabis won a Nobel for a discriminative model, a structure predictor, and the entire field celebrated. What's quieter is that the next generation of tools, the ones Profluent is building on top of ProGen3, aren't predicting what proteins look like. They're writing proteins that don't exist yet. That distinction gets lost when people he

The question this raises for me: at what point does compressing NDA review time stop being the binding constraint, and the trial structure itself becomes the ceiling? Ten months is real progress. But the 45 percent of drug development time I traced back to batch submission latency in my own reporting sits upstream of NDA filing, not downstream. Arvinas still ran a Phase 1, then a Phase 2, then a

```json [ { "post_index": 0, "cluster_ids": [8], "claim": "Medicare coverage for GLP-1 drugs at $50/month signals major policy shift", "argument_type": "empirical_claim", "stance": "neutral_analysis", "hyde_excerpt": "The Trump administration's announcement of Medicare coverage for weight-loss drugs at $50 monthly represents a watershed moment for GLP-1 access policy. Thi

```json [ { "post_index": 2, "matched_article_id": 524, "match_confidence": 88, "match_reason": "Tweet reports Trump announcing Medicare patients will receive weight-loss drugs at $50/month; article analyzes exactly this mechanism — the GLP-1 Bridge extension to Dec 2027 creating a $50/month copay structure as de facto Medicare anti-obesity policy — including the specific cost-sh

The $50 number is real but it's a cost-sharing cap that existed inside the BALANCE Model's Part D design, and that model's Part D leg was paused on April 21 because CMS couldn't get enough major sponsors to apply. The 80 percent NAMBA-weighted enrollment threshold in Section 2.3.1 required essentially simultaneous opt-in from Humana, UnitedHealth, CVS Aetna, Centene, Elevance, Cigna, and Kaiser, a

The $50 figure is real but the framing skips a lot. That cost-sharing cap comes directly from the BALANCE Model's EA/EGWP plan structure, and the reason it matters is that the model's Part D leg just got paused because CMS couldn't get the NAMBA-weighted 80% enrollment threshold met, meaning the channel that would have delivered that $50 cap to most Medicare beneficiaries doesn't actually exist fo

The $50 number is doing a lot of work in that headline. The Bridge extension already caps cost-sharing at $50/month for EA and EGWP plans, but the bigger structural problem is that there's no Part D formulary channel to actually deliver that price at scale in 2027, because BALANCE's 80% NAMBA-weighted threshold required simultaneous opt-in from virtually every major sponsor and they missed it by a

$50/month Medicare coverage is a real shift, but the harder question is what the coverage model looks like operationally, because price alone doesn't solve the persistence problem. Prime Therapeutics' data shows only 1-in-12 patients still on therapy after three years, and roughly 60% of lost weight returns within 12 months of stopping. Medicare covering the drug at $50 doesn't change that math at

```json [ { "post_index": 0, "prediction": "reject", "confidence": 78, "reason": "GLP-1 pricing announcement without healthcare system impact analysis. Matches [glp1_peptide_macro_or_personal_framing] exclusion rule—focuses on price point ($50/month) and policy announcement without

```json [ { "category": "ai_safety_vulnerability_incident_tangential", "summary": "Posts about AI safety failures, security breaches, or adversarial attacks that lack healthcare-specific impact analysis.", "exclusion_rule": "Exclude posts that report AI safety incidents, security vulne